Replacing factor-dependency with that for lysozyme: Affordable culture of IL-6-dependent hybridoma by transfecting artificial cell surface receptor

被引:14
作者
Kawahara, M
Natsume, A
Terada, S
Kato, K
Tsumoto, K
Kumagai, I
Miki, M
Mahoney, W
Ueda, H [1 ]
Nagamune, T
机构
[1] Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan
[2] Univ Fukui, Sch Engn, Dept Appl Chem & Biotechnol, Fukui 9108507, Japan
[3] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan
[4] Quantum Dot Corp, Res & Dev, Hayward, CA 94545 USA
[5] Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1138656, Japan
关键词
growth control; hybridoma; chimeric receptor; gp130; antibody variable region; hen egg lysozyme;
D O I
10.1002/bit.1132
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytokines and growth factors are indispensable for the propagation and maintenance of factor-dependent mammalian cells. However, cytokines are often so expensive that the use of factor-dependent cells for industrial applications such as protein production is often not practical. Based on our previous design of a binary hen egg lysozyme (HEL)-specific receptor composed of portions of the anti-HEL antibody and the erythropoietin receptor, a new pair of chimeric receptors having the intracellular domain of gp130 were made and transfected to an interleukin-6 (IL-6)-dependent hybridoma, 7TD1. The clone expressing the two new receptors showed clear HEL dose-dependent cell growth and monoclonal antibody production in both serum-based and serum-free media without IL-6. These results establish the feasibility of applying receptor design to tailor cells for the inexpensive induction of cell growth for the purpose of producing therapeutic products. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:416 / 423
页数:8
相关论文
共 39 条
[1]  
Bentley G A, 1996, EXS, V75, P301
[2]   Crystal structure of a cytokine-binding region of gp130 [J].
Bravo, J ;
Staunton, D ;
Heath, JK ;
Jones, EY .
EMBO JOURNAL, 1998, 17 (06) :1665-1674
[3]   Therapeutic antibody fragments with prolonged in vivo half-lives [J].
Chapman, AP ;
Antoniw, P ;
Spitali, M ;
West, S ;
Stephens, S ;
King, DJ .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783
[4]  
Deng J, 1997, Chin J Biotechnol, V13, P247
[5]   A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor [J].
Dittrich, E ;
Haft, CR ;
Muys, L ;
Heinrich, PC ;
Graeve, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5487-5494
[6]   Physiology of cultured animal cells [J].
Doverskog, M ;
Ljunggren, J ;
Öhman, L ;
Häggström, L .
JOURNAL OF BIOTECHNOLOGY, 1997, 59 (1-2) :103-115
[7]   Ectopic expression of the erythropoietin receptor in a murine interleukin-6-dependent plasmacytoma cell line (TEPC-2027) confers proliferative responsiveness to erythropoietin [J].
Feger, F ;
Dubart, A ;
Lacout, C ;
DusanterFourt, I ;
Mayeux, P ;
Vainchenker, W ;
Dumenil, D .
BLOOD, 1997, 89 (02) :435-445
[8]   Genetic optimization of recombinant glycoprotein production by mammalian cells [J].
Fussenegger, M ;
Bailey, JE ;
Hauser, H ;
Mueller, PP .
TRENDS IN BIOTECHNOLOGY, 1999, 17 (01) :35-42
[9]   MOLECULAR-CLONING AND EXPRESSION OF AN IL-6 SIGNAL TRANSDUCER, GP130 [J].
HIBI, M ;
MURAKAMI, M ;
SAITO, M ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
CELL, 1990, 63 (06) :1149-1157
[10]  
HORNE C, 1982, J IMMUNOL, V129, P660